Investigational drug · Phase 2
STRO-002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasm Malignant.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "STRO-002"
First trial start
2023
Nov 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STRO-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasm Malignant
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "STRO-002" as an intervention, largest first.
Sutro Biopharma, Inc.Industry
NCT05870748 · 600 participants · Start Jul 12, 2023 · Primary completion Aug 26, 2025
Drug: Luveltamab tazevibulin; Pegfilgrastim and 4 more · For: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer and 2 more
Sites: Tucson, Arizona; Daly City, California; San Diego, California · 63 sites in all
Sutro Biopharma, Inc.Industry
NCT03748186 · 136 participants · Start Feb 1, 2019 · Primary completion Jun 4, 2024
Drug: STRO-002 · For: Ovarian Cancer; Ovarian Carcinoma; Ovary Cancer and 4 more
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 27 sites in all
Sutro Biopharma, Inc.Industry
NCT05200364 · 58 participants · Start Mar 22, 2022 · Primary completion Jun 1, 2025
Drug: STRO-002; Bevacizumab · For: Ovarian Cancer; Ovarian Carcinoma; Ovary Cancer and 2 more
Sites: Tampa, Florida; Philadelphia, Pennsylvania; Nashville, Tennessee · 6 sites in all
Tasly Pharmaceutical Group Co., LtdIndustry
NCT06238687 · 19 participants · Start Nov 8, 2023 · Primary completion Jun 6, 2025
Drug: STRO-002 · For: Neoplasm Malignant
Sites: Chengdu, China
Sutro Biopharma, Inc.Industry
NCT06679582 · 1 participants · Start Dec 4, 2024 · Primary completion Jan 21, 2025
Drug: Luveltamab tazevibulin · For: Acute Myeloid Leukemia (AML)
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 36 sites in all
Sutro Biopharma, Inc.Industry
NCT06555263 · 0 participants · Start Aug 21, 2024 · Primary completion May 1, 2025
Drug: Luveltamab tazevibulin · For: Lung Cancer; Lung Cancer Metastatic; Lung Cancer, Nonsmall Cell and 3 more
Sites: La Jolla, California; Washington D.C., District of Columbia; Lake Mary, Florida · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis.
Kim ET, Kim JH, Park EY, et al. · Cancer Med 2024
- Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC, Powell SS, Pothuri B · Am Soc Clin Oncol Educ Book 2023
- Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
Li X, Zhou S, Abrahams CL, et al. · Mol Cancer Ther 2023
- Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate.
Tang T, Le Q, Castro S, et al. · Blood Adv 2022
Also in development for Neoplasm Malignant
- MK-1084CalderasibPhase 38 trials
Merck & Co. · Non-small Cell Lung Cancer, Colon Adenocarcinoma, Rectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.